SEC-sourced researchBeta

CRSP

CRISPR Therapeutics AG

US markets

Data passport

CIK: 0001674416
Exchange: Nasdaq
Business activity: — · SIC 2836
Financial inputs: 6/6
Filing date: Oct 6, 2026
SEC registry record: Operating company

Last updated: Oct 7, 2026, 10:04 PM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

CRSP · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	371,206,000.0000	Feb 12, 2026
December 2024	37,314,000.0000	Feb 12, 2026
December 2025	3,510,000.0000	Feb 12, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	3,510,000.0000	-581,599,000.0000	-345,014,000.0000	2,265,243,000.0000	343,430,000.0000	Feb 12, 2026
December 2024	37,314,000.0000	-366,252,000.0000	-142,774,000.0000	2,242,034,000.0000	309,954,000.0000	Feb 12, 2026
December 2023	371,206,000.0000	-153,610,000.0000	-260,375,000.0000	—	—	Feb 12, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$3.51M	December 2025	Feb 12, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$37.31M	December 2024	Feb 12, 2026	10-K
Net incomeNetIncomeLoss	-$581.6M	December 2025	Feb 12, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	-$345.01M	December 2025	Feb 12, 2026	10-K
Total assetsAssets	$2.27B	December 2025	Feb 12, 2026	10-K
Total liabilitiesLiabilities	$343.43M	December 2025	Feb 12, 2026	10-K

New filings

Explore methodology ↗